VSV. Shaganenko

V. Shaganenko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


V. Shaganenko has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pathogenetic foundations and modern approaches to the pharmacotherapy of broncho pneumonia in production animal

    by V. Shaganenko, S. Rublenko, N. Kozii, R. Shaganenko, N. Avramenko, S. Shmayun

    Bronchopneumonia is among the most prevalent respiratory disorders in animals, causing significant economic losses in livestock production due to decreased productivity, treatment costs, and mortality of young animals. This review summarizes current knowledge on the prevalence, etiology, and pathophysiological mechanisms of bronchopneumonia in animals, emphasizing the roles of microbial–viral associations, cytokine cascade activation, oxidative stress, and hypoxic tissue injury. Modern pharmacotherapeutic strategies are analyzed, integrating etiological, pathogenetic, and symptomatic approaches. Particular attention is paid to the combined use of antimicrobial agents with anti-infl ammatory, mucolytic, antioxidant, and immunomodulatory drugs aimed at restoring respiratory function and systemic homeostasis. The paper discusses the shortcomings of conventional antibiotic therapy, such as the emergence of antibiotic resistance and the insufficient consideration of pathophysiological conditions in diseased animals. Promising research directions are outlined, including bacteriophage therapy, antimicrobial peptides, nanocarrier-based drug delivery systems, natural antioxidants, and probiotic formulations. The importance of pathophysiologically grounded and personalized approaches to therapy, considering immune reactivity, respiratory microbiome composition, and environmental management, is emphasized. The presented synthesis highlights strategies to enhance therapeutic efficacy, reduce relapse frequency, and achieve sustainable recovery in animals affected by bronchopneumonia. Keywords: bronchopneumonia, production animals, pathophysiology, treatment, antibiotic resistance, pharmacological therapy.

  • The use of neuroleptics, sedatives and anesthetics for anxiolytic therapy in animals

    by K. Lukyanenko, O. Poroshynska, R. Shaganenko, N. Koziі, S. Shmayun, V. Shaganenko, O. Koshelev, A. Polishchuk, V. Koziy

    An important area for improving antidepressant treatment is the expansion of the indications for neuroleptics, anesthetics and sedatives. All these drugs have pronounced neurotropic effects. The aim of our work is to study the published scientifc evidence on the potential of neuroleptics, anesthetics and sedatives for anxiolytic therapy. A systematic literature review was used to search for publications on the topic of the study. The PubMed database (https://pubmed.ncbi.nlm.nih.gov) was used to search for scientifc articles. The literature data indicates that ketamine is used to treat recurrent anxiety in both humans and animals. It provides rapid and sustained relief of anxiety symptoms in a variety of its clinical presentations. The anxiolytic effect occurs within the frst 12 hours after administration and remains effective for 1 to 2 weeks. The anxiolytic effect of ketamine is due to its effect on hippocampal neurotropic factor activity. Diazepam can signifcantly reduce anxiety and depressive symptoms as well as neuroinflammation in brain-injured mice. It causes a dose-dependent increase in motor activity. In combination with metformin, diazepam is the preferred treatment for type 2 diabetes mellitus in stressed animals. Intermittent use of diazepam is useful to avoid the development of physical dependence when the drug is used for a long period of time. Acepromazine is promising to be used for anxiolytic effect in animals. A combined protocol with acepromazine signifcantly reduced signs of stress, anxiety and aggression during veterinary visits and had an anxiolytic effect in dogs. Acepromazine reduces the negative effects of transport stress in wild ungulates. Dexmedetomidine is used for sedation in both human and veterinary medicine. This drug is a promising candidate for the experimental treatment of stress-related diseases such as anxiety disorders or post-traumatic stress disorder. We believe that further research in this area should be conducted in controlled comparative studies to determine the optimal doses and duration of administration of potential anxiolytics, considering the species, age, sex, physiological state and other relevant clinical parameters of the animals studied. Therefore, systematic and detailed studies will help us not only to understand the effectiveness, but also to provide safe and individualized treatment. This research can improve our understanding of the use of anxiolytics in veterinary practice, which is of key importance for improving the quality of animal welfare. In our opinion, the use of anesthetics, neuroleptics and sedatives, which are now widely used for sedation or general anesthesia, opens new possibilities for the treatment of behavioral and anxiety disorders in animals. Key words: anxiety, veterinary medicine, neuroleptics, sedatives, ketamine, acepromazine, diazepam, medetomidine.

  • Pharmacological and legal aspects of the drugs in modern animal husbandry

    by N. Kozii, R. Shaganenko, N. Avramenko, V. Shaganenko, S. Rublenko

    In modern conditions, the responsibility of the farmer and veterinarian to ensure the proper quality of livestock products by observing the deadlines for the withdrawal of medicinal products is increasing, especially in cases of unauthorized use of medical therapeutic agents. The purpose of the study was to get acquainted with the pharmacological and legal aspects of the use of medicinal products in modern animal husbandry and to determine the role and tasks of the veterinarian in ensuring the quality and safety of products of animal origin. An analysis of legal acts of various countries regulating the use of medicinal products outside of the instructions in modern animal husbandry was carried out. The analysis of the results of the study allows us to state that in view of the intensifcation of animal husbandry and the prospects for the development of trade in products of animal origin within the framework of the WTO and with EU countries, the issue outside the instructions for the use of medicinal products for farm animals in Ukraine requires attention. The attitude to the use of medicinal products should be reflected in the relevant legal acts regulating the work of veterinary medicine doctors. In Ukraine, the main document for veterinary medicine regarding the rules for the use of veterinary drugs is the Law "On Veterinary Medicine". According to it, it is allowed to use for farm animals only medicines entered in the state register. An important task of the pharmacological support of the animal husbandry industry should be the study of the pharmacokinetics of drugs in cases of their use in animals outside of the instructions. We believe that the further study of the experience of European countries in solving the issue of pharmacological support for the production of livestock products and the development of regulatory documents in Ukraine is a promising direction of research. Key words: animal husbandry, product safety, medicinal products, instructions, application.